As the first company in New Zealand to be granted a medical cannabis cultivation license, our focus is on cultivating, GMP manufacturing and clinically proving medicinal cannabis products for both domestic and international markets.
New Zealand is uniquely positioned due to it’s open legal environment, strong agricultural skill base, global reputation for high quality products and compliant medical system that has already legalised CBD as a prescription medicine and provides access to higher THC products.
Hikurangi Cannabis Company offers a unique combination of experience in plant-based bioactives and drug discovery, cannabis genetics and international partnerships that may be unmatched in New Zealand.
Hikurangi has already completed initial cultivation and processing research. In 2018 we established a breeding facility for both indoor and outdoor cultivation of cannabis, a multi-year breeding programme as part of a global plant genetics collaboration and associated analytical testing. GAP cultivation and GMP medicine manufacturing facilities for Hikurangi are currently under construction in the Tairāwhiti region.
We anticipate securing a medicines manufacturing license by the first quarter of 2020 which will allow us to begin commercial production.
We aim to have full scale export production as well as final product form manufacture in place to coincide with domestic market expansion positioning us as a premier New Zealand producer of medical cannabis products.